NVCN - NVCN STOCK NEWS

Neovasc (NVCN) has announced its participation in the LSI Europe 2022 Emerging MedTech Summit in the UK, taking place from September 21-24, 2022. CEO Fred Colen will present on September 23 at 11:10 am BST. Interested attendees can register to view the live stream of his presentation. Neovasc specializes in medical devices for cardiovascular treatment, including the Reducer and Tiara products, which are currently under investigation and have been commercially available in Europe since 2015.

Neovasc Inc. (NVCN) announced the introduction of new ICD-10-CM codes for diagnosing refractory angina, effective October 1, 2022. This development enhances the ability to identify patients suffering from this severe condition, which often leads to hospitalization and high healthcare resource utilization. The primary new code, I20.2 Refractory Angina Pectoris, is part of nine newly created codes. The COO of Neovasc emphasized the importance of these codes for measuring treatment costs and clinical outcomes. Neovasc's Reducer is currently under clinical investigation in the U.S. via the COSIRA-II trial.

Neovasc (NASDAQ: NVCN) announced its participation in the TCT 2022 conference in Boston from September 16-19, showcasing new data on the Neovasc Reducer™ aimed at treating refractory angina in patients with non-obstructive coronary artery disease (ANOCA). Dr. Shmuel Banai will present early results on September 19, highlighting the Reducer's impact on coronary flow reserve. Additionally, a symposium on September 18 will focus on the Reducer's clinical application and the COSIRA-II trial. The Reducer is CE-marked in the EU and currently under investigation in the U.S.

Neovasc, a specialty medical device company, has announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference, scheduled for September 12-14, 2022, in New York City. CEO Fred Colen will present on September 13 at 1:30 pm ET. A live webcast of the presentation will be available, along with a recording accessible for 90 days via Neovasc's website. Neovasc develops products for the cardiovascular market, including Reducer for refractory angina and Tiara™ for mitral valve disease, both under clinical investigation.

Neovasc Inc. (NASDAQ, TSX: NVCN) reported a record revenue of $818,000 for Q2 2022, marking a 29% increase year-over-year. The company advanced its COSIRA II clinical trial, enrolling 40 patients and receiving FDA approval for a protocol supplement. Neovasc has initiated direct sales in the UK, enhancing its market presence. Total expenses decreased by 8% to approximately $8.8 million, contributing to reduced operating losses of approximately $8.2 million. Neovasc ended Q2 2022 with about $37.6 million in cash.

Neovasc Inc. (NVCN) will announce financial results for Q2 2022 on August 11, 2022. CEO Fred Colen and CFO Chris Clark will host a conference call at 4:30 PM EDT to discuss the outcomes. The company develops innovative cardiovascular products, including Reducer and Tiara™, with ongoing clinical investigations in the U.S. and internationally. These developments align with the growing cardiovascular market, presenting opportunities for Neovasc's product offerings.

Neovasc announced FDA approval for a protocol supplement to the COSIRA-II Investigational Device Exemption Trial, expanding patient eligibility and adding two imaging sub-studies for its Reducer device. This supplement allows the enrollment of up to 270 additional patients with non-obstructive coronary artery disease and those unable to perform treadmill tests. The trial aims to investigate the Reducer’s effectiveness in patients with refractory angina, with the primary endpoint being exercise tolerance improvement. The approval is seen as a significant step for treating women and a broader patient population.

On July 5, 2022, Neovasc announced an expansion into the UK, effective July 1, 2022, to enhance direct sales of its Neovasc Reducer, which is now reimbursable by NHS England. This decision follows NICE guidelines supporting the Reducer's use for refractory angina patients. Neovasc has hired its first two employees in the UK and plans further growth in its sales team. The Reducer aims to improve blood flow and alleviate angina symptoms, impacting millions globally.

Neovasc Inc. (NVCN) announced its participation in the 2022 Sidoti & Co. Summer Small Cap Virtual Investor Conference on June 15-16. Chief Operating Officer Bill Little will present on June 15 at 1:45 pm ET. The presentation can be accessed online, and a recording will be available for 90 days post-event.

Neovasc specializes in medical devices for the cardiovascular market, including the Reducer for refractory angina and Tiara™ for mitral valve disease, both under clinical investigation.